Opsonization of T1M1 group A Streptococcus: dynamics of antibody production and strain specificity.

A chemiluminescence method was used to study opsonization of group A Streptococcus (GAS) of serotype T1M1 in serum samples ("sera") obtained from Swedish patients with invasive and noninvasive GAS infection and from healthy blood donors. Acute-phase serum samples ("acute sera") generally demonstrated low ability to opsonize the patient's own GAS isolate, regardless of clinical manifestation. Only approximately 15% of serum samples obtained from healthy blood donors demonstrated high opsonic activity against a standard T1M1 strain. Opsonization of 62 T1M1 isolates (obtained during 1980-1998) by a single immune serum sample showed considerable variation; this indicates that high opsonic immunity may develop only against the infecting isolate or identical clones. T1M1 GAS isolated from 1987 through 1990 were better opsonized by the immune serum sample than were isolates obtained before 1987 or after 1990, a finding that suggests a temporal change of the surface properties that affect opsonization.

[1]  E. Kaplan,et al.  Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera. , 1999, The Journal of infectious diseases.

[2]  J. Andersson,et al.  Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. , 1999, The Journal of infectious diseases.

[3]  D. Stevens,et al.  Type-specific opsonophagocytosis of group A Streptococcus by use of a rapid chemiluminescence assay. , 1999, The Journal of infectious diseases.

[4]  J. Andersson,et al.  Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Musser,et al.  Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G. Lindahl,et al.  Expression of two different antiphagocytic M proteins by Streptococcus pyogenes of the OF+ lineage. , 1998, Journal of immunology.

[7]  J. Vuopio‐Varkila,et al.  Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland. , 1997, The Journal of infectious diseases.

[8]  C. Jorup-Rönström,et al.  Erysipelas: clinical and bacteriologic spectrum and serological aspects. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  E. Kaplan.  Recent epidemiology of group A streptococcal infections in North America and abroad: an overview. , 1996, Pediatrics.

[10]  M. Wessels,et al.  Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci , 1996, Infection and immunity.

[11]  A. Podbielski,et al.  M‐related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes , 1996, Molecular microbiology.

[12]  A. Österlund.  Epidemiological observations on Streptococcus pyogenes serotype T1 in Uppsala county, Sweden 1989–1995 , 1996 .

[13]  D. Stevens.  Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. , 1995, Emerging infectious diseases.

[14]  J. Zabriskie,et al.  Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. , 1995, The Journal of infectious diseases.

[15]  U. Andersson,et al.  Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B , 1994, Infection and immunity.

[16]  B. Schwartz,et al.  Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome , 1993, Infection and immunity.

[17]  M. P. Harbaugh,et al.  Nucleotide substitutions and small‐scale insertion produce size and antigenic variation in group A streptococcal M1 protein , 1993, Molecular microbiology.

[18]  J. P. Davis,et al.  Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. , 1993, JAMA.

[19]  S. Holm,et al.  Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. , 1992, The Journal of infectious diseases.

[20]  L. Burman,et al.  Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. , 1991, The Journal of infectious diseases.

[21]  V. Fischetti,et al.  Streptococcal M protein: molecular design and biological behavior , 1989, Clinical Microbiology Reviews.

[22]  R. Zwaag,et al.  Acquisition of Group A streptococcal M protein antibodies , 1985, Pediatric infectious disease.

[23]  R. Facklam,et al.  Type-specific immunity and pharyngeal acquisition of group A Streptococcus. , 1982, American journal of epidemiology.

[24]  R. Lancefield.  Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[25]  R. Lancefield.  PERSISTENCE OF TYPE-SPECIFIC ANTIBODIES IN MAN FOLLOWING INFECTION WITH GROUP A STREPTOCOCCI , 1959, The Journal of experimental medicine.

[26]  R. Lancefield.  DIFFERENTIATION OF GROUP A STREPTOCOCCI WITH A COMMON R ANTIGEN INTO THREE SEROLOGICAL TYPES, WITH SPECIAL REFERENCE TO THE BACTERICIDAL TEST , 1957, The Journal of experimental medicine.

[27]  F. W. Denny,et al.  Type-specific streptococcal antibody. , 1957, The Journal of clinical investigation.

[28]  J. Musser,et al.  An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. , 1997, JAMA.